These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

947 related articles for article (PubMed ID: 33519200)

  • 1. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.
    Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A
    Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Nanotechnology in the COVID-19 Pandemic.
    Yang D
    Int J Nanomedicine; 2021; 16():623-649. PubMed ID: 33531805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.
    Tammam SN; El Safy S; Ramadan S; Arjune S; Krakor E; Mathur S
    J Control Release; 2021 Sep; 337():258-284. PubMed ID: 34293319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment.
    Dawre S; Maru S
    Life Sci; 2021 Aug; 278():119561. PubMed ID: 33915132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention.
    Solanki R; Shankar A; Modi U; Patel S
    Mater Today Chem; 2023 Apr; 29():101478. PubMed ID: 36950312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development.
    Wang MY; Zhao R; Gao LJ; Gao XF; Wang DP; Cao JM
    Front Cell Infect Microbiol; 2020; 10():587269. PubMed ID: 33324574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes.
    Al-Hatamleh MAI; Hatmal MM; Alshaer W; Rahman ENSEA; Mohd-Zahid MH; Alhaj-Qasem DM; Yean CY; Alias IZ; Jaafar J; Ferji K; Six JL; Uskoković V; Yabu H; Mohamud R
    Eur J Pharmacol; 2021 Apr; 896():173930. PubMed ID: 33545157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-performance antiviral nano-systems as a shield to inhibit viral infections: SARS-CoV-2 as a model case study.
    Sadique MA; Yadav S; Ranjan P; Verma S; Salammal ST; Khan MA; Kaushik A; Khan R
    J Mater Chem B; 2021 Jun; 9(23):4620-4642. PubMed ID: 34027540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrochemical SARS-CoV-2 Sensing at Point-of-Care and Artificial Intelligence for Intelligent COVID-19 Management.
    Kaushik AK; Dhau JS; Gohel H; Mishra YK; Kateb B; Kim NY; Goswami DY
    ACS Appl Bio Mater; 2020 Nov; 3(11):7306-7325. PubMed ID: 35019473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.
    Weiss C; Carriere M; Fusco L; Capua I; Regla-Nava JA; Pasquali M; Scott JA; Vitale F; Unal MA; Mattevi C; Bedognetti D; Merkoçi A; Tasciotti E; Yilmazer A; Gogotsi Y; Stellacci F; Delogu LG
    ACS Nano; 2020 Jun; 14(6):6383-6406. PubMed ID: 32519842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging nanotechnology role in the development of innovative solutions against COVID-19 pandemic.
    Bhutta ZA; Kanwal A; Ali M; Kulyar MF; Yao W; Shoaib M; Ashar A; Mahfooz A; Ijaz M; Ijaz N; Asif M; Nawaz S; Mahfooz MR; Kanwal T
    Nanotechnology; 2021 Sep; 32(48):. PubMed ID: 34320471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomedical application, drug delivery and metabolic pathway of antiviral nanotherapeutics for combating viral pandemic: A review.
    Mukherjee S; Mazumder P; Joshi M; Joshi C; Dalvi SV; Kumar M
    Environ Res; 2020 Dec; 191():110119. PubMed ID: 32846177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).
    Seyfoori A; Shokrollahi Barough M; Mokarram P; Ahmadi M; Mehrbod P; Sheidary A; Madrakian T; Kiumarsi M; Walsh T; McAlinden KD; Ghosh CC; Sharma P; Zeki AA; Ghavami S; Akbari M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential inhibitors of SARS-CoV-2: recent advances.
    Jamalipour Soufi G; Iravani S
    J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise.
    Joseph S; Nair B; Nath LR
    Curr Mol Med; 2021; 21(10):888-913. PubMed ID: 33563197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy.
    Mirtaleb MS; Mirtaleb AH; Nosrati H; Heshmatnia J; Falak R; Zolfaghari Emameh R
    Biomed Pharmacother; 2021 Jun; 138():111518. PubMed ID: 33774315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.